Lundbeck is partnering with Charles River Laboratories to enhance the discovery of neuroscience treatments through their AI-powered drug discovery platform, Logica.
“To make a significant impact on neurological diseases today, you need to be able to work on unprecedented molecular targets with causal biology,” said Tarek Samad, Ph.D., head of global research at Lundbeck. “Partnering with Logica will allow us to use a unique tool set, including AI-driven approaches, to overcome drug design challenges which often slow down the translation of promising targets into drug candidates.”
This collaboration will allow Lundbeck to streamline the development of optimized small molecules for creating novel therapies.